Valuation: CSL Limited

Market Cap 64.1B 58.46B 54.05B 48.78B 91.86B 5,990B 95.49B 653B 258B 3,233B 240B 235B 10,209B P/E 2027 *
22x
P/E 2028 * 20x
Enterprise Value 73.31B 66.86B 61.82B 55.79B 105B 6,851B 109B 747B 295B 3,698B 275B 269B 11,676B EV / Sales 2027 *
4.65x
EV / Sales 2028 * 4.47x
Free-Float
99.97%
Yield 2027 *
2.25%
Yield 2028 * 2.38%
1 day-1.70%
1 week-4.95%
Current month-7.04%
1 month-1.35%
3 months+17.08%
6 months+90.50%
Current year+14.24%
1 week 32.56
Extreme 32.56
34.6
1 month 32.56
Extreme 32.56
36.88
Current year 16.01
Extreme 16.01
36.88
1 year 16.01
Extreme 16.01
36.88
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
57.42
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-4.95% - - 64.1B
-2.32%-3.79%+34.24%+133.69% 1,232B
-2.15%-2.75%+36.35%+82.05% 656B
-2.33%-3.04%+22.29%+106.80% 506B
-0.69%+0.37%+31.53%+69.78% 382B
-3.90%-6.39%+42.88%+35.41% 340B
-1.35%-0.95%+28.90%+56.34% 294B
-1.13%-1.80%+0.59%+33.00% 278B
-3.07%-5.17%+29.04%+67.26% 240B
-0.75%-0.44%+32.87%+123.96% 210B
Average -1.94%-2.30%+28.74%+78.70% 460B
Weighted average by Cap. -2.08%-2.67%+30.56%+91.62%

Financials

2027 *2028 *
Net sales 15.76B 14.37B 13.29B 11.99B 22.59B 1,473B 23.48B 160B 63.44B 795B 59.12B 57.88B 2,510B 16.31B 14.87B 13.75B 12.41B 23.37B 1,524B 24.29B 166B 65.65B 823B 61.18B 59.9B 2,597B
Net income 2.82B 2.57B 2.38B 2.15B 4.04B 264B 4.2B 28.73B 11.36B 142B 10.58B 10.36B 449B 3.13B 2.86B 2.64B 2.38B 4.49B 293B 4.67B 31.9B 12.61B 158B 11.75B 11.51B 499B
Net Debt 9.22B 8.4B 7.77B 7.01B 13.21B 861B 13.73B 93.85B 37.1B 465B 34.57B 33.85B 1,468B 8.83B 8.05B 7.44B 6.72B 12.65B 825B 13.15B 89.89B 35.53B 445B 33.11B 32.42B 1,406B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
18/11/26 $32.90 -1.70% 796,386
17/11/26 $33.47 -1.56% 46,932
16/11/26 $34.00 -1.19% 42,681
13/11/26 $34.41 -0.75% 35,616
12/11/26 $34.67 +0.16% 38,476
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
133.84USD
Average target price
134.60USD
Spread / Average Target
+0.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited